The Effects of 5% Imiquimod Cream on Bowen's Disease / 대한피부과학회지
Korean Journal of Dermatology
;
: 1410-1416, 2006.
Article
in Korean
| WPRIM
| ID: wpr-107424
ABSTRACT
BACKGROUND:
Imiquimod is an immune response modifier which works as a Toll-like receptor 7 agonist which induces interferon and other cytokines through the innate immune system and stimulates cell-mediated immunity through T cells. Imiquimod has been shown to be efficacious as a topical treatment for variable cutaneous neoplasms including Bowen's disease.OBJECTIVE:
The purpose of this study was to evaluate the efficacy and safety of 5% imiquimod cream for the treatment of Bowen's disease.METHODS:
Thirty one lesions from 13 patients with Bowen's disease were treated with 5% imiquimod cream, 3 times per week at night, until complete clearance of lesions had occurred. During the follow-up period, the duration of therapeutic response, clearance rate, side effects and recurrence were recorded. Biopsy specimens from five patients after treatment completion were obtained to confirm tumor clearance.RESULTS:
Complete clinical response was obtained in 30 lesions (96.8%) from 12 patients, and a partial clinical response was observed in a palmar lesion of 1 patient. The duration of complete response ranged from 4 to 24 weeks, and mean duration was 11.8 weeks. All patients showed mild to moderate local skin reactions such as erythema, erosion, crusting, itching, burning, and pain. No-one experienced systemic adverse effects during topical application. After 3 to 26 months follow-up of the patients who had shown complete clearance, no-one encountered recurrence.CONCLUSION:
5% imiquimod cream appears to be safe and effective for the treatment of Bowen's disease, and so therefore may be promising future treatment for this condition.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Pruritus
/
Recurrence
/
Skin
/
Biopsy
/
Bowen's Disease
/
Burns
/
T-Lymphocytes
/
Follow-Up Studies
/
Cytokines
/
Interferons
Type of study:
Observational study
/
Prognostic study
Limits:
Humans
Language:
Korean
Journal:
Korean Journal of Dermatology
Year:
2006
Type:
Article
Similar
MEDLINE
...
LILACS
LIS